Bioventus Launches GELSYN-3 HA for Treatment of Knee Osteoarthritis Pain

Bioventus commenced U.S. launch of GELSYN-3™ three-injection hyaluronic acid for relief of pain associated with knee osteoarthritis. The regimen is intended to relieve pain for up to 6 months.

Bioventus acquired exclusive U.S. distribution rights for GELSYN from Institut Biochimique in 1Q16. The product had received FDA premarket approval in...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us